The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.
If you’re looking at treatment options for diabetes, you may want to learn more about insulin aspart. This includes information about cost. Insulin aspart is a prescription drug that acts quickly to ...
Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes patients, enhancing treatment accessibility. The GEMELLI-1 trial confirmed Merilog's noninferiority to the ...
This paper provides a review and evaluation of the published evidence relating to the efficacy, safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with ...
HAMBURG, Germany -- Faster-acting insulin aspart was safe for pregnant women with type 1 or 2 diabetes and resulted in fewer events of hypoglycemia, the randomized CopenFast trial found. The mean ...
Established rapid-acting and long-acting insulin analogues have enabled more patients with type 1 diabetes mellitus to reach better glucose targets, with lower hypoglycaemia rates and a better quality ...
COPENHAGEN, Jan 8 (Reuters) - Denmark's Novo Nordisk (NOVOb.CO), opens new tab said on Monday its COMBINE 3 phase 3a drug trial had shown that a weekly injection of IcoSema was superior in controlling ...
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like its reference ...
Clin Drug Invest. 2004;24(12):695-717. Finally, subcutaneous insulin aspart every 1 or 2 hours was a well tolerated and cost-effective alternative to a standard intravenous protocol of regular insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results